GlassScriptPhysician profile
Timothy P Newton
NPI 1356703060
$2,330.03
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $63.79 · 2021: $570 · 2022: $860 · 2023: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $434.49 | 2021-2023 | |
| Lilly USA, LLC | $232.65 | 2021-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $191.03 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $182.69 | 2020-2023 | Farxiga |
| Pfizer INC. | $146.80 | 2021-2023 | |
| Amgen INC. | $135.53 | 2021-2023 | Evenity, Prolia, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $110.31 | 2022 | |
| Glaxosmithkline, LLC. | $86.19 | 2021-2023 | Arexvy, Rotarix, Bexsero |
| Hologic Sales and Service, LLC | $60.81 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Takeda Pharmaceuticals U.S.A., INC. | $55.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.11 | 2022-2023 | Synjardy, Tradjenta |
| Exact Sciences Corporation | $49.97 | 2023 | Cologuard Collection Kit |
| Sobi, INC | $48.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $47.32 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $45.19 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $43.53 | 2021 | |
| Neurocrine Biosciences, INC. | $42.70 | 2021-2023 | Ingrezza |
| Cranial Technologies, INC | $41.29 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $40.11 | 2022-2023 | Rexulti, Abilify Maintena |
| Ironshore Pharmaceuticals INC. | $35.75 | 2022 | |
| Novo Nordisk INC | $33.51 | 2021-2023 | Ozempic, Rybelsus |
| Corium, LLC | $24.88 | 2023 | Azstarys |
| Allergan, INC. | $23.56 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $22.13 | 2022 | |
| Sanofi Pasteur INC. | $20.94 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.42 | 2023 | Strensiq |
| Horizon Therapeutics Plc | $16.90 | 2023 | Krystexxa |
| Edwards Lifesciences Corporation | $15.47 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kowa Pharmaceuticals America, INC. | $15.43 | 2023 | Livalo |
| Idorsia Pharmaceuticals US INC | $15.38 | 2023 | Quviviq |
| Gilead Sciences, INC. | $14.60 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.32 | 2022 | |
| Nevro Corp. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Newton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.